Boundless Bio and Serapha Bio announce a merger and secure $230 million in private placement, co-led by RA Capital Management and RTW Investments.
Amount Raised
$230 Million
Round Type
Series A
Hat YaiBiotechnologyHealth CareTherapeuticsInvestors
Description
Boundless Bio and Serapha Bio have entered into a definitive merger agreement, with Serapha securing commitments for a pre-closing private placement of $230 million. The financing will provide runway through Phase 2 completion and Phase 3 initiation for the investigational therapy SERP-01. The merger will allow the combined entity to focus on treating severe Alpha-1 Antitrypsin Deficiency. The expected cash and cash equivalents will fund operations into the second half of 2029.
Quick answer
Serapha Bio raised $230 Million in a Series A round, dated June 25, 2026. Investors: Decheng Capital, Balyasny Asset Management, Logos Capital, LifeSci Venture Partners, Eventide Asset Management, Janus Henderson Investors, Vivo Capital and Casdin Capital. Serapha Bio is based in Hat Yai, Songkhla Province, Thailand.
- How much did Serapha Bio raise?
- Serapha Bio raised $230 Million in a Series A round on June 25, 2026.
- Who invested in Serapha Bio?
- Decheng Capital, Balyasny Asset Management, Logos Capital, LifeSci Venture Partners, Eventide Asset Management, Janus Henderson Investors, Vivo Capital and Casdin Capital are named as investors in this round.
- What does Serapha Bio do?
- Serapha Bio is a privately held company focused on developing treatments for genetic diseases.
- Where is Serapha Bio based and how big is it?
- Serapha Bio is based in Hat Yai, Songkhla Province, Thailand.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Serapha Bio that raised within 45 days of this round, from Fundz verified event records.
- Opal Therapeutics raised $1.3M (Grant) on August 7, 2026.
- Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
- Expedition raised $115M (Series B) on August 5, 2026.
- Acasti raised $10M on August 4, 2026.
- GentiBio raised $1.2M (Grant) on August 2, 2026.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
Who to call at Serapha Bio, and when
A new round usually means Serapha Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Serapha Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Serapha Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Serapha Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Serapha Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansSerapha Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.